# Semaglutide vs Liraglutide: Key Differences

**By TelosRX Editorial Team** · 2026-09-18

Both semaglutide and liraglutide belong to the same class of medications — GLP-1 receptor agonists — yet they differ meaningfully in how often you take them, how much weight the evidence shows they help you manage, and what is available through a licensed telehealth provider. This head-to-head comparison covers the research so you can have an informed conversation with a licensed provider.

## What are semaglutide and liraglutide?

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases in response to food. It signals your brain that you have eaten, slows gastric emptying, and reduces glucagon secretion. Both semaglutide and liraglutide are synthetic analogs of this hormone that bind to GLP-1 receptors and mimic its effects — but they differ in molecular structure, half-life, and dosing convenience.

**Liraglutide** was developed by Novo Nordisk and approved by the FDA in 2010 for type 2 diabetes (Victoza) and in 2014 for chronic weight management (Saxenda). It shares about 97% of its amino acid sequence with native GLP-1 and has a half-life of roughly 13 hours, which means once-daily injections are required to maintain therapeutic levels.

**Semaglutide**, also from Novo Nordisk, arrived later: Ozempic (2017) for type 2 diabetes, Wegovy (2021) for obesity, and Rybelsus (2019) as an oral daily tablet. Structural modifications — including fatty acid chain attachment — extend its half-life to approximately seven days, enabling once-weekly subcutaneous dosing. This dosing convenience, combined with stronger clinical weight-loss outcomes, has made semaglutide the dominant GLP-1 option in recent years.

## Head-to-head comparison

| Factor | Semaglutide | Liraglutide |
| --- | --- | --- |
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Dosing frequency | Once weekly (injectable); once daily (oral Rybelsus) | Once daily (injectable only) |
| FDA approval — type 2 diabetes | Ozempic (2017) | Victoza (2010) |
| FDA approval — obesity | Wegovy (2021) | Saxenda (2014) |
| Average weight reduction in trials | ~14–17% (STEP-1, STEP-5) | ~5–8% (SCALE Obesity) |
| Cardiovascular outcome trial | SUSTAIN-6 / SELECT (positive) | LEADER (positive) |
| Compounding availability | Yes, under federal compounding regulations | Not routinely compounded |
| Oral form available | Yes (Rybelsus; compounded oral semaglutide) | No  |

## Weight loss results: what the trials found

The most closely studied outcome for both medications is body weight reduction, measured in randomized controlled trials lasting 52 to 72 weeks.

In the STEP-1 trial published in 2021, adults without diabetes who received 2.4 mg weekly subcutaneous semaglutide (Wegovy dose) lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% for placebo. A substantial proportion of participants lost 15% or more. The STEP-5 trial extended this to two years and found mean weight loss of 15.2%, indicating durability of effect.

The SCALE Obesity and Prediabetes trial (2015) found that adults taking 3 mg daily liraglutide (Saxenda dose) lost an average of 8.4% of body weight compared with 2.8% for placebo over 56 weeks.

Meta-analyses consistently find semaglutide produces approximately double the percentage weight loss of liraglutide at approved obesity doses. The difference is attributed to semaglutide's greater GLP-1 receptor binding affinity and its sustained half-life, which allows more continuous receptor engagement between doses.

## Cardiovascular outcomes

Both medications have completed large cardiovascular outcome trials (CVOTs) and both demonstrated benefit in people with established cardiovascular disease or high risk — an important clinical consideration beyond weight management alone.

The LEADER trial (liraglutide, 2016) enrolled adults with type 2 diabetes and high cardiovascular risk. It found a statistically significant 13% relative reduction in major adverse cardiovascular events (MACE: cardiovascular death, nonfatal heart attack, nonfatal stroke) compared with placebo over a median 3.8 years.

SUSTAIN-6 (semaglutide, 2016) was a non-inferiority trial that found a 26% reduction in MACE for injectable semaglutide. The larger SELECT trial (2023) enrolled adults with established cardiovascular disease but without diabetes and found a 20% reduction in MACE with semaglutide 2.4 mg, independent of diabetes status. This was the first GLP-1 CVOT conducted exclusively in non-diabetic individuals.

## Side effects and tolerability

The side effect profiles of both medications overlap considerably because they act through the same receptor pathway. The most common adverse effects — nausea, vomiting, diarrhea, and constipation — reflect GLP-1 activity in the gut and tend to peak during dose escalation before improving.

Both carry a boxed warning regarding a risk of thyroid C-cell tumors observed in rodent studies at doses not directly comparable to clinical use. The human significance of this finding remains unestablished. Both are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN-2).

Pancreatitis has been reported rarely with both agents. Both should be used cautiously in individuals with a history of pancreatitis. Neither should be combined with insulin or other GLP-1 agents without provider guidance.

Because liraglutide requires daily injections versus semaglutide's weekly schedule, cumulative injection frequency differs meaningfully — an important practical consideration for adherence and injection site tolerability.

## Compounding and telehealth access

Compounded semaglutide is available through federally regulated 503B outsourcing facilities and 503A compounding pharmacies when a licensed provider determines it is clinically appropriate. Compounded formulations allow individualized dosing and are often more accessible from a cost standpoint than brand-name Ozempic or Wegovy, which carry retail prices exceeding $1,000 per month without insurance.

Compounded liraglutide is not routinely available and is not currently offered at TelosRX. Its daily injection requirement, shorter half-life, and substantially lower weight-loss evidence compared with semaglutide mean that compounded semaglutide is the preferred choice for most patients pursuing GLP-1-based weight management through a telehealth-first platform.

Compounded medications are not FDA-approved. Approval for any compounded GLP-1 requires evaluation by a licensed provider; approval is not guaranteed. Individual results vary.

## Which medication fits your situation?

Neither semaglutide nor liraglutide is appropriate to use without a licensed provider's evaluation. The right choice between GLP-1 options depends on your metabolic health history, cardiovascular risk profile, tolerance of specific side effects, dosing preference, and treatment goals — all of which a provider reviews before writing any prescription.

For patients pursuing evidence-based weight management through asynchronous telehealth, compounded semaglutide consistently offers the strongest body of weight-loss data, weekly dosing convenience, and an established cardiovascular benefit profile across multiple large trials. Liraglutide remains an effective GLP-1 option in certain clinical contexts, particularly where once-daily injectable dosing is preferred or where the patient has prior clinical experience with it.

See also: [Tirzepatide vs Semaglutide](/blogs/glp1/tirzepatide-vs-semaglutide-compounded-glp1-comparison), [Compounded Semaglutide in 2026](/blogs/glp1/compounded-semaglutide-telehealth-2026), and [Semaglutide Side Effects, Answered](/blogs/glp1/semaglutide-side-effects-questions-answered).

## Frequently asked questions

### Is semaglutide more effective than liraglutide for weight loss?

Clinical trials show semaglutide produces roughly twice the percentage weight loss on average compared with liraglutide at their respective approved obesity doses. Both are effective GLP-1 receptor agonists, but semaglutide's structural design gives it greater receptor binding affinity and a longer half-life that sustains its effects between weekly doses.

### Can I switch from liraglutide to semaglutide?

Transitions between GLP-1 medications are evaluated individually by a licensed provider. A washout period or dose adjustment protocol may be recommended depending on your current dose and clinical context. This should not be done without medical guidance.

### Is compounded liraglutide available?

Compounded liraglutide is not routinely offered through telehealth-first providers. Compounded semaglutide is available through providers like TelosRX, subject to evaluation by a licensed provider who determines whether it is appropriate for your individual health situation.

_TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._

Start your private evaluation at [TelosRX](https://telosrx.com).

**Tags:** compounded GLP-1, GLP-1, GLP-1 comparison, liraglutide, semaglutide, weight loss

---

> Source: [Telos RX](https://www.telosrx.com/blogs/glp1/semaglutide-vs-liraglutide-key-differences)
